Developer docs
API playgroundTry for free, no card

Search company profiles

Diatech Diabetes

Full company profile

uuid00041hs

Namestring
Diatech Diabetes
Legal namestring
Diatech Diabetes, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Diatech Diabetes, Inc. was a privately-held medical device company founded in 2018 and incorporated in Delaware, with operational roots in Memphis. The company developed SmartFusion®, a proprietary software platform consisting of a mobile app and an algorithm designed to monitor insulin pump infusion accuracy and detect infusion-set failures in real time. The technology is intended to integrate with insulin pumps and automated insulin delivery (AID) systems, generating alerts when failures occur and providing data to manage continuous 24/7 wear of insulin delivery devices, thereby improving safety for people living with Type 1 diabetes. At the time of acquisition, SmartFusion® was in development and not commercially available; no customers, revenue, or pricing had been established.

The company was led by co-founders John Wilcox (CEO) and Luis E. Blanco (CTO), both with personal connections to Type 1 diabetes, supported by a broader leadership team including CSO John Clark Gray and COO Nicholas Robert Cooper. Development was funded through a combination of equity raises (including Right Side Capital Management and a 2024 SEC Form D offering of up to $150,000), grant awards from Breakthrough T1D (formerly JDRF), the Consortium for Technology & Innovation in Pediatrics (CTIP), and NIH-NIDDK, and accelerator participation in ZeroTo510. The company received the 2023 Breakthrough T1D Industry Discovery & Development Partnership (IDDP) Award in recognition of its R&D progress. In October 2025, DEKA Research & Development — developer of the twiist® Automated Insulin Delivery system — acquired Diatech's core assets and intellectual property and hired select leadership, ending Diatech's operation as an independent entity and absorbing SmartFusion® into DEKA's diabetes technology portfolio.

Short descriptiontext

Diatech Diabetes was a pre-commercial medical device company that developed SmartFusion®, a software platform for real-time monitoring of insulin pump infusion accuracy and failure detection in people with Type 1 diabetes. Acquired by DEKA Research & Development in October 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMemphis, United States
HQ citystring
Memphis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
insulin infusion monitoring, diabetes device software, automated insulin delivery, medical device integration, pump infusion safety
Industry2 codes
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Health Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Licensing/Integration
TypeLicensing Royalties
Description

Pre-commercial company developing software technology for integration with insulin pump manufacturers. Revenue model not yet established as technology is in development.

breakthrought1d.org
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1SmartFusion®
Description

A software platform that monitors for medication delivery failure in infusion pumps. When integrated with an insulin pump, the SmartFusion® mobile app and algorithm measures the accuracy of daily insulin delivery, generates alerts when a failure occurs with the pump's connected infusion site, and provides data to manage the 24/7 wear of the device on the body.

breakthrought1d.org
Core offering1 text field

Diatech Diabetes develops SmartFusion®, a software platform comprising a mobile app and proprietary algorithm that monitors insulin pump infusion accuracy and detects medication delivery failures in real-time. When integrated with an insulin pump, the platform measures daily insulin delivery accuracy, generates alerts when infusion site failures occur, and provides data to manage the continuous 24/7 wear of the device. The technology is designed to improve insulin delivery safety for people living with diabetes, particularly as automated insulin delivery systems become more prevalent.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Diatech Diabetes developed SmartFusion®, a software platform that monitors insulin pump infusion accuracy and detects failures in real-time to improve insulin delivery safety for people with diabetes. The platform consists of the SmartFusion® algorithm and a mobile app. The technology is currently in development and not commercially available.

Product and service1 record
1SmartFusion®
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

DEKA Research & Development acquired Diatech Diabetes's core assets and intellectual property in October 2025. The deal included ownership of Diatech's proprietary SmartFusion® technology and hiring of select Diatech leadership. DEKA, developer of the twiist® Automated Insulin Delivery (AID) system, viewed the acquisition as strongly aligning with their mission to develop safe and accurate diabetes technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of the t:slim X2 insulin pump with Control-IQ AID technology. Tandem is a direct peer because it operates in the same AID market where SmartFusion® aims to provide infusion-accuracy monitoring, and competes for the same Type 1 diabetes customer base.

TypeRegional player
Description

Swiss-based developer of the mylife Loop AID system using the YpsoPump. Ypsomed is a regional peer operating a competing AID pump platform outside the US where SmartFusion® could potentially be licensed.

TypeBroad incumbent
Description

Developer of the MiniMed 780G AID system with SmartGuard technology and a leading global diabetes device franchise. Medtronic is a broad incumbent peer with vertically integrated pump, CGM, and AID algorithm capabilities that could natively compete with SmartFusion®-style monitoring.

TypeDirect peer
Description

Maker of the Omnipod 5 tubeless patch pump with integrated AID. Insulet is a direct peer in the wearable insulin-delivery space where SmartFusion®'s continuous wear monitoring is most relevant.

TypeEmerging player
Description

Developer of the CamAPS FX AID algorithm used with various insulin pumps across Europe. CamDiab is an emerging peer in AID control software, with overlapping interest in infusion-set monitoring and closed-loop safety.

TypeDirect peer
Description

Developer of the iLet bionic pancreas AID system. Beta Bionics is a direct peer operating in the AID category with proprietary dosing algorithms where infusion-monitoring complementary software like SmartFusion® could be integrated.

TypeEmerging player
Description

Non-profit maker of the Tidepool Loop DIY-AID-loop-derived app and diabetes data platform. Tidepool is an emerging peer operating in diabetes data software and AID control, adjacent to SmartFusion®'s monitoring software positioning.

TypeDirect peer
Description

Acquirer of Diatech and developer of the twiist® Automated Insulin Delivery system. DEKA is the most directly comparable peer as it owns SmartFusion® and will integrate the monitoring software into its insulin pump platform.

TypeBroad incumbent
Description

Leading continuous glucose monitor (CGM) manufacturer whose sensors are integrated into most AID systems. Dexcom is a broad incumbent peer whose G7/G8 CGM data feeds AID control algorithms, making it adjacent infrastructure for SmartFusion®'s safety-monitoring use case.

10Bigfoot Biomedical
TypeEmerging player
Description

Developer of the Bigfoot Unity smart insulin pen system and connected diabetes management platform. Bigfoot is an emerging peer in connected diabetes drug-delivery technology with overlapping mission of simplifying and securing insulin delivery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Diatech Diabetes

Digital Health Softwarediatechdiabetes.com

Diatech Diabetes was a pre-commercial medical device company that developed SmartFusion®, a software platform for real-time monitoring of insulin pump infusion accuracy and failure detection in people with Type 1 diabetes. Acquired by DEKA Research & Development in October 2025.

What Diatech Diabetes does

Diatech Diabetes, Inc. was a privately-held medical device company founded in 2018 and incorporated in Delaware, with operational roots in Memphis. The company developed SmartFusion®, a proprietary software platform consisting of a mobile app and an algorithm designed to monitor insulin pump infusion accuracy and detect infusion-set failures in real time. The technology is intended to integrate with insulin pumps and automated insulin delivery (AID) systems, generating alerts when failures occur and providing data to manage continuous 24/7 wear of insulin delivery devices, thereby improving safety for people living with Type 1 diabetes. At the time of acquisition, SmartFusion® was in development and not commercially available; no customers, revenue, or pricing had been established.

The company was led by co-founders John Wilcox (CEO) and Luis E. Blanco (CTO), both with personal connections to Type 1 diabetes, supported by a broader leadership team including CSO John Clark Gray and COO Nicholas Robert Cooper. Development was funded through a combination of equity raises (including Right Side Capital Management and a 2024 SEC Form D offering of up to $150,000), grant awards from Breakthrough T1D (formerly JDRF), the Consortium for Technology & Innovation in Pediatrics (CTIP), and NIH-NIDDK, and accelerator participation in ZeroTo510. The company received the 2023 Breakthrough T1D Industry Discovery & Development Partnership (IDDP) Award in recognition of its R&D progress. In October 2025, DEKA Research & Development — developer of the twiist® Automated Insulin Delivery system — acquired Diatech's core assets and intellectual property and hired select leadership, ending Diatech's operation as an independent entity and absorbing SmartFusion® into DEKA's diabetes technology portfolio.

Diatech Diabetes firmographics

Firmographics
Name
Diatech Diabetes
Legal name
Diatech Diabetes, Inc.
Website
https://diatechdiabetes.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
1–10 employees
Short description
Diatech Diabetes was a pre-commercial medical device company that developed SmartFusion®, a software platform for real-time monitoring of insulin pump infusion accuracy and failure detection in people with Type 1 diabetes. Acquired by DEKA Research & Development in October 2025.
Ownership category
akta.pro rank

Diatech Diabetes industry classification

Industry
Product category
Digital Health Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Insulin infusion monitoring
  • Diabetes device software
  • Automated insulin delivery
  • Medical device integration
  • Pump infusion safety

Where Diatech Diabetes is headquartered

Location

Headquarters

HQ city
Memphis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Diatech Diabetes business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing/Integration: Pre-commercial company developing software technology for integration with insulin pump manufacturers. Revenue model not yet established as technology is in development.

Go-to-market motion1 record

Diatech Diabetes product offering

Product offering

Core offering

Diatech Diabetes develops SmartFusion®, a software platform comprising a mobile app and proprietary algorithm that monitors insulin pump infusion accuracy and detects medication delivery failures in real-time. When integrated with an insulin pump, the platform measures daily insulin delivery accuracy, generates alerts when infusion site failures occur, and provides data to manage the continuous 24/7 wear of the device. The technology is designed to improve insulin delivery safety for people living with diabetes, particularly as automated insulin delivery systems become more prevalent.

Product overview

Diatech Diabetes developed SmartFusion®, a software platform that monitors insulin pump infusion accuracy and detects failures in real-time to improve insulin delivery safety for people with diabetes. The platform consists of the SmartFusion® algorithm and a mobile app. The technology is currently in development and not commercially available.

Differentiator

Problem solved

Functional benefit

Brands

  • SmartFusion®: A software platform that monitors for medication delivery failure in infusion pumps. When integrated with an insulin pump, the SmartFusion® mobile app and algorithm measures the accuracy of daily insulin delivery, generates alerts when a failure occurs with the pump's connected infusion site, and provides data to manage the 24/7 wear of the device on the body.

Products and services

  • SmartFusion®

Companies that use Diatech Diabetes

Customer profile

Segments1 record

Ideal customer profiles1 record

Diatech Diabetes technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature2 records

Diatech Diabetes partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • DEKA Research & DevelopmentcoreStrategic or Co-development Partner · 7 October 2025DEKA Research & Development acquired Diatech Diabetes's core assets and intellectual property in October 2025. The deal included ownership of Diatech's proprietary SmartFusion® technology and hiring of select Diatech leadership. DEKA, developer of the twiist® Automated Insulin Delivery (AID) system, viewed the acquisition as strongly aligning with their mission to develop safe and accurate diabetes technology.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Diatech Diabetes competitors and assessment

Company assessment

Direct peers

  • Tandem Diabetes Care: Developer of the t:slim X2 insulin pump with Control-IQ AID technology. Tandem is a direct peer because it operates in the same AID market where SmartFusion® aims to provide infusion-accuracy monitoring, and competes for the same Type 1 diabetes customer base.
  • Insulet Corporation: Maker of the Omnipod 5 tubeless patch pump with integrated AID. Insulet is a direct peer in the wearable insulin-delivery space where SmartFusion®'s continuous wear monitoring is most relevant.
  • Beta Bionics: Developer of the iLet bionic pancreas AID system. Beta Bionics is a direct peer operating in the AID category with proprietary dosing algorithms where infusion-monitoring complementary software like SmartFusion® could be integrated.
  • DEKA Research & Development: Acquirer of Diatech and developer of the twiist® Automated Insulin Delivery system. DEKA is the most directly comparable peer as it owns SmartFusion® and will integrate the monitoring software into its insulin pump platform.

Regional players

  • Ypsomed: Swiss-based developer of the mylife Loop AID system using the YpsoPump. Ypsomed is a regional peer operating a competing AID pump platform outside the US where SmartFusion® could potentially be licensed.

Broad incumbents

  • Medtronic Diabetes: Developer of the MiniMed 780G AID system with SmartGuard technology and a leading global diabetes device franchise. Medtronic is a broad incumbent peer with vertically integrated pump, CGM, and AID algorithm capabilities that could natively compete with SmartFusion®-style monitoring.
  • Dexcom: Leading continuous glucose monitor (CGM) manufacturer whose sensors are integrated into most AID systems. Dexcom is a broad incumbent peer whose G7/G8 CGM data feeds AID control algorithms, making it adjacent infrastructure for SmartFusion®'s safety-monitoring use case.

Emerging players

  • CamDiab: Developer of the CamAPS FX AID algorithm used with various insulin pumps across Europe. CamDiab is an emerging peer in AID control software, with overlapping interest in infusion-set monitoring and closed-loop safety.
  • Tidepool: Non-profit maker of the Tidepool Loop DIY-AID-loop-derived app and diabetes data platform. Tidepool is an emerging peer operating in diabetes data software and AID control, adjacent to SmartFusion®'s monitoring software positioning.
  • Bigfoot Biomedical: Developer of the Bigfoot Unity smart insulin pen system and connected diabetes management platform. Bigfoot is an emerging peer in connected diabetes drug-delivery technology with overlapping mission of simplifying and securing insulin delivery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Diatech Diabetes social profiles

Digital presence

Diatech Diabetes financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Diatech Diabetes leadership team

Management profile

Number of profiles

Profiles4 records

Diatech Diabetes funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Diatech Diabetes M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diatech Diabetes

What does Diatech Diabetes do?

Diatech Diabetes develops SmartFusion®, a software platform comprising a mobile app and proprietary algorithm that monitors insulin pump infusion accuracy and detects medication delivery failures in real-time. When integrated with an insulin pump, the platform measures daily insulin delivery accuracy, generates alerts when infusion site failures occur, and provides data to manage the continuous 24/7 wear of the device. The technology is designed to improve insulin delivery safety for people living with diabetes, particularly as automated insulin delivery systems become more prevalent.

Is Diatech Diabetes a public or private company?

Diatech Diabetes is a private company. It is classified as corporate owned and is currently acquired.

When was Diatech Diabetes founded?

Diatech Diabetes was founded in 2018. It employs 1 to 10 people.

Where is Diatech Diabetes based?

Diatech Diabetes is headquartered in Memphis, United States, in the North America region.

How does Diatech Diabetes make money?

One revenue line is on record: technology Licensing/Integration.

Who are Diatech Diabetes's main competitors?

Direct peers on record are Tandem Diabetes Care, Insulet Corporation, Beta Bionics and DEKA Research & Development. Ypsomed is listed as a regional player. Broad incumbents are Medtronic Diabetes and Dexcom. Emerging players are CamDiab, Tidepool and Bigfoot Biomedical.

Does Diatech Diabetes have an API?

No public API is recorded for Diatech Diabetes.

What industry is Diatech Diabetes in?

Diatech Diabetes's product category is Digital Health Software. Its primary akta.pro industry code is HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals